U.S. District Court Grants Abbott Laboratories's Request For A Preliminary Injunction Against Biaxin(R) XL Generics; Andrx Corporation Shares Drop 8% On Ruling

ABBOTT PARK, Ill., Nov. 10 /PRNewswire-FirstCall/ -- The U.S. District Court in Chicago today granted Abbott's request for a preliminary injunction that will prevent unauthorized generic copies of Abbott's Biaxin XL from Ranbaxy and Andrx. It is expected that a full patent infringement trial will take place in 2006, although no date has been set.

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 60,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.

CONTACT: Media: Melissa Brotz, +1-847-935-3456, or mobile:+1-847-772-2761, or Catherine Bryan, +1-847-936-6722, or mobile:+1-312-209-0250; or Investors: John Thomas, +1-847-938-2655

Web site: http://www.abbott.com/